Live
BioPharma DiveSummit pulls $500M share sale a day after announcing itEndpoints NewsDrugmakers are turning to logistics providers as trade disruptions linger, DHL exec saysBioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecificsBioWorldInnovo Therapeutics synthesizes new NMT1 inhibitors
Endpoints News 26 nov. 2025

Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN

Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN

Original
Contenu indisponible. Consultez la source originale.